Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Esperion Therapeutics Inc shares valued at $17,573 were sold by Looker Benjamin on Sep 17 ’25. At $2.80 per share, Looker Benjamin sold 6,267 shares. The insider’s holdings dropped to 393,670 shares worth approximately $0.99 million following the completion of this transaction.
Also, Koenig Sheldon L. sold 28,427 shares, netting a total of over 79,254 in proceeds. Following the sale of shares at $2.79 each, the insider now holds 1,518,831 shares.
Before that, Halladay Benjamin had sold 7,046 shares from its account. In a trade valued at $19,785, the Chief Financial Officer traded Esperion Therapeutics Inc shares for $2.81 each. Upon closing the transaction, the insider’s holdings decreased to 7,046 shares, worth approximately $1.2 million.
As published in their initiating research note from Goldman on December 18, 2024, Esperion Therapeutics Inc [ESPR] has been a Neutral and the price target has been revised to $4. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid December. As of June 20, 2024, BofA Securities has decreased its “Neutral” rating to a “an Underperform” for ESPR. Earlier on January 03, 2024, BofA Securities downgraded its rating. Their new recommendation was “a Neutral” for ESPR stock which previously was a “a Buy”.
Analyzing ESPR Stock Performance
On last trading session, Esperion Therapeutics Inc [NASDAQ: ESPR] plunged -6.67% to $2.52. The stock’s lowest price that day was $2.515, but it reached a high of $2.755 in the same session. During the last five days, there has been a drop of approximately -1.95%. Over the course of the year, Esperion Therapeutics Inc shares have jumped approximately 27.92%.
Is Esperion Therapeutics Inc subject to short interest?
Stocks of Esperion Therapeutics Inc saw a sharp rise in short interest on 2025-09-30 jumping by 5.35 million shares to 27.69 million. Data from Yahoo Finance shows that the short interest on 2025-08-29 was 22.35 million shares. A jump of 19.3% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.93 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.93.
Which companies own the most shares of Esperion Therapeutics Inc (ESPR)?
In terms of Esperion Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 9 in the next 12 months, up nearly 233.33% from the previous closing price of $2.7. Analysts anticipate Esperion Therapeutics Inc stock to reach 9 by 2025, with the lowest price target being 9. In spite of this, 8 analysts ranked Esperion Therapeutics Inc stock as Buy at the end of 2025.
